Health IT Generated PROs to Improve Outcomes in Cirrhosis

Status Completed

Clinical Trial Summary

SPECIFIC AIM 1: To evaluate in a multi-center, randomized trial the effectiveness of PROs elicited using PatientBuddy and EncephalApp on the prevention of avoidable 30 day readmissions in patients with cirrhosis and their caregivers compared to standard of care.

Clinical Trial Description

Cirrhosis affects more than 6 million US patients and is a major burden on patients, caregivers and the healthcare system. Patients with cirrhosis are prone to clinical and psycho-social issues that may predict hospitalization, re-hospitalizations and death. Important patient-reported outcomes (PRO) such as impaired daily functioning, sleep, cognition and pain are widely prevalent in patients with cirrhosis. These changes can independently impact hospitalizations, re-hospitalizations and death in cirrhotic patients. The investigators have studied the impact of these PRO using traditional and computerized scales such as PROMIS (Patient-reported outcomes measurement information system). With the increasing spread of health-related electronic devices, the relevance of health IT in the management of chronic diseases such as cirrhosis is paramount. The team has already developed and used several health IT advances to educate patients and their caregivers in inpatient and outpatient settings. These tools are Patient Buddy to define patients regarding factor preventing readmission, and EncephalApp Stroop to detect cognitive dysfunction in cirrhosis. As part of a funded AHRQ R21, PatientBuddy, which has undergone multiple refinements in response to feedback from patients, caregivers and administering staff, is being used by the study team to prevent readmissions to Virginia Commonwealth University Medical Center (VCU). However the evaluation of these tools in a multi-center study that adapts to the status of the patients and their caregivers is an important step towards improvement in cirrhosis-related outcomes. In addition, PROs that are elicited and monitored when the patients are outside the hospital will advance the field by making them integral parts of clinical management. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03564626
Study type	Interventional
Source	Virginia Commonwealth University
Contact
Status	Completed
Phase	N/A
Start date	June 22, 2018
Completion date	May 22, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01884415` - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis	Phase 3
Recruiting	`NCT05014594` - Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT	Phase 2
Not yet recruiting	`NCT03631147` - The Effect of Rifaximin on Portal Vein Thrombosis	N/A
Completed	`NCT04939350` - Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
Completed	`NCT02528760` - To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis	N/A
Recruiting	`NCT05484206` - Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434	Phase 1
Not yet recruiting	`NCT05538546` - Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients
Not yet recruiting	`NCT04053231` - Hepatocarcinoma Recurrence on the Liver Study - Part2
Recruiting	`NCT02983968` - Use of the French Healthcare Insurance Database
Completed	`NCT02705534` - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1	Phase 3
Completed	`NCT02596880` - Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics	Phase 3
Completed	`NCT02247414` - Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection	Phase 4
Completed	`NCT02016196` - Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS	Phase 3
Withdrawn	`NCT01956864` - Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer	Phase 1
Completed	`NCT02113631` - Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir	N/A
Completed	`NCT01447537` - Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis	N/A
Completed	`NCT01362855` - Advance Care Planning Evaluation in Hospitalized Elderly Patients
Active, not recruiting	`NCT01205074` - ¹³C-Methacetin Breath Test (MBT) Methodology Study	Phase 2/Phase 3
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A
Completed	`NCT01231828` - Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Health IT Generated PROs to Improve Outcomes in Cirrhosis — HEROIC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms